RSS
1 Jun 2021

Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases

Author: admintech | Filed under: Press Release

HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ — Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC)…

This entry was posted on Tuesday, June 1st, 2021 at 7:16 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»